SAN FRANCISCO -- Merriman Curhan Ford (NASDAQ: MERR) announced today that it has hired John W. Chambers and Michael A. Margolis, R.Ph. as managing directors in its health care investment banking practice. Chambers, in addition to heading the practice, will serve on the investment bank's management and commitment committees.
"John and Michael are strong investment bankers with excellent health care transaction experience and deep industry contacts," said Jon Merriman, chief executive officer of Merriman Curhan Ford. "As a veteran investment banker, John will help us establish Merriman Curhan Ford as a premier platform for emerging-growth companies in the life sciences space, and will be an added voice of experience and leadership on the management committee. Their skills and corporate client base also complements Panel Intelligence, our primary market research subsidiary, as well as our strengths in equity research and institutional sales and trading. John and Michael have what it takes to advise emerging-growth life sciences companies in this difficult financing environment. I welcome both of them to the firm."
Chambers and Margolis will be based out of the firm's New York office.
Chambers was most recently co-head of investment banking at Rodman & Renshaw. He has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors. Chambers earned his M.B.A. from Columbia Business School and his B.S. in mechanical engineering from Union College.
Margolis was most recently senior vice president of health care investment banking at Rodman & Renshaw. He had extensive financial and pharmaceutical industry experience before joining Rodman. Margolis worked at Novartis Pharmaceuticals Corporation in several roles, including as a director in the global business development and licensing group. He was an equity research analyst at Ursus Capital, and he began his career as at Eli Lilly & Company as a senior pharmaceutical representative. Margolis is a registered pharmacist with an M.B.A. from New York University's Stern School of Business and a pharmacy degree from Rutgers University, College of Pharmacy.
About Merriman Curhan Ford
Merriman Curhan Ford (NASDAQ:MERR) is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to www.mcfco.com.
Note to Investors
This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-Q filed on August 11, 2008. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-Q filed on August 11, 2008, together with this press release and the financial information contained herein, is available on our website by going to www.mcfco.com and clicking on "Investor Relations."
No comments:
Post a Comment